Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced that it has granted equity inducement awards to two new employees as part of its 2022 Employment Inducement Award Plan. Approved by the Compensation Committee of the Board of Directors, these awards comply with Nasdaq Listing Rule 5635(c)(4). The new employees have been granted options to purchase a total of 325,000 shares of Terns common stock. These options, with a 10-year term, carry an exercise price of $3.56 per share, corresponding to the closing price on May 1, 2025. The vesting schedule spans four years, contingent upon the employees' continued service.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.